The Budd-Chiari syndrome: outcome after treatment with the transjugular intrahepatic portosystemic shunt

Rössle, Martin; Olschewski, Manfred; Siegerstetter, V.; Berger, É.; Kurz, Katharina; Grandt, Daniel

doi:10.1016/j.surg.2003.09.005

Cited by 151 publications

(120 citation statements)

References 38 publications

Supporting

Mentioning

109

Contrasting

Unclassified

Order By: Relevance

“…Covered TIPS in BCS has shown lower TIPS dysfunction rate (33% vs 87% in uncovered group) and higher primary patency rate at 1-year (67% vs 19% in uncovered group) in one recent series comprising nine patients in a covered TIPS group [94] . Another series using covered TIPS in eight patients showed there was no need for revisions during almost one year of follow-up [91] . In our study, TIPS was used as a primary treatment in the subset of the patients with long-segment HV thrombosis with or without IVCT.…”

Section: Discussionmentioning

confidence: 91%

“…In the last decade, the use of TIPS in BCS is increasingly described in the world literature [81][82][83][84][85][86][87][88][89][90][91][92][93][94] . In cases with severe liver dysfunction requiring liver transplantation, TIPS used as an interim bridge to transplantation, can improve the situation dramatically [4] .…”

Section: Discussionmentioning

confidence: 99%

“…Technical success for TIPS ranges from 75% to 100% in various works [ of TIPS dysfunction (present in 40% to 75% if followed up for more than two years [80,82,84,90,91,93] ) necessitates reinter vention in up to 70% of cases [1,[87][88][89]91] , giving a revision rate of 1.4 revisions per patient [91] . TIPS related complications occur in less than 20% of patients [91] . TIPS provided a survival rate of 85% at four years in one series and 74% at five years in another series [82,91] .…”

Section: Discussionmentioning

confidence: 99%

“…TIPS related complications occur in less than 20% of patients [91] . TIPS provided a survival rate of 85% at four years in one series and 74% at five years in another series [82,91] . Covered TIPS in BCS has shown lower TIPS dysfunction rate (33% vs 87% in uncovered group) and higher primary patency rate at 1-year (67% vs 19% in uncovered group) in one recent series comprising nine patients in a covered TIPS group [94] .…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Changing spectrum of Budd-Chiari syndrome in India with special reference to non-surgical treatment

Amarapurkar¹,

Punamiya²,

Patel³

2008

WJG

View full text Add to dashboard Cite

AIM:To evaluate patterns of obstruction, etiological spectrum and non-surgical treatment in patients with Budd-Chiari syndrome in India. METHODS:Forty-nine consecutive cases of BuddChiari syndrome (BCS) were prospectively evaluated. All patients with refractory ascites or deteriorating liver function were, depending on morphology of inferior vena cava (IVC) and/or hepatic vein (HV) obstruction, triaged for radiological intervention, in addition to anticoagulation therapy. Asymptomatic patients, patients with diuretic-responsive ascites and stable liver function, and patients unwilling for surgical intervention were treated symptomatically with anticoagulation. RESULTS:Mean duration of symptoms was 41.5 ± 11.2 (range = 1-240) mo. HV thrombosis (HVT) was present in 29 (59.1%), IVC thrombosis in eight (16.3%), membranous obstruction of IVC in two (4%) and both IVC-HV thrombosis in 10 (20.4%) cases. Of 35 cases tested for hypercoagulability, 27 (77.1%) were positive for one or more hypercoagulable states. Radiological intervention was technically successful in 37/38 (97.3%): IVC stenting in seven (18.9%), IVC balloon angioplasty in two (5.4%), combined IVC-HV stenting in two (5.4%), HV stenting in 11 (29.7%), transjugular intrahepatic portosystemic shunt (TIPS) in 13 (35.1%) and combined TIPS-IVC stenting in two (5.4%). Complications encountered in follow-up: death in five, re-stenosis of the stent in five (17.1%), hepatic encephalopathy in two and hepatocellular carcinoma in one patient. Of nine patients treated medically, two showed complete resolution of HVT. CONCLUSION:In our series, HVT was the predominant cause of BCS. In the last five years with the availability of sophisticated tests for hypercoagulability, etiologies were defined in 85.7% of cases. Non-surgical management was successful in most cases.

show abstract

Section: Discussionmentioning

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Changing spectrum of Budd-Chiari syndrome in India with special reference to non-surgical treatment

Amarapurkar¹,

Punamiya²,

Patel³

2008

WJG

View full text Add to dashboard Cite

show abstract

“…TIPS has been shown to be effective as the treatment for BCS in early experiences [21][22][23] and can be successful also in the technically difficult case of extension of thrombosis to the portal vein tree [24,25] . Moreover, a multi-center experience provided long-term data on TIPS treatment for 147 BCS patients not responding to medical treatment or recanalization.…”

Section: Treatments For Budd-chiari Syndromementioning

confidence: 99%

Timing of transjugular intrahepatic portosystemic shunt for Budd-Chiari syndrome: An Italian hepatologist’s perspective

Mancuso

2017

Journal of Translational Internal Medicine

View full text Add to dashboard Cite

Budd-Chiari syndrome (BCS) management flow-chart is derived from experts' opinion and is not evidence-based. Guidelines suggest BCS management should follow a stepwise strategy: medical therapy as first-line treatment, revascularization or transjugular intrahepatic portosystemic shunt (TIPS) if no response to medical therapy, and liver transplant as rescue therapy. Recent evidence suggests that only medical therapy results in a bad long-term outcome. The biggest criticism of guidelines is the indication that BCS should receive further treatment only when hemodynamic consequences of portal hypertension become clinically evident. Recent data support that in BCS liver fibrosis could arise from chronic microvascular ischemia. A reasoning model of BCS physiopathology is that impaired hepatic vein outflow has hemodynamic consequences on portal hypertension development and causes hepatic fibrosis and liver failure through chronic ischemic damage. On this assumption is the concept that relieving liver congestion could ameliorate liver function and prevent development of BCS complications. Recently, early interventional treatment with TIPS for BCS has been reported to be effective. Early TIPS seems to be the best option for BCS management. Future multicenter controlled studies should compare the outcome of BCS treated with early interventional treatment compared with stepwise strategy.

show abstract

Disorders of the Hepatic Veins and Hepatic Sinusoids

Valla¹

2007

Textbook of Hepatology

View full text Add to dashboard Cite

The Budd-Chiari syndrome: outcome after treatment with the transjugular intrahepatic portosystemic shunt

Cited by 151 publications

References 38 publications

Changing spectrum of Budd-Chiari syndrome in India with special reference to non-surgical treatment

Changing spectrum of Budd-Chiari syndrome in India with special reference to non-surgical treatment

Timing of transjugular intrahepatic portosystemic shunt for Budd-Chiari syndrome: An Italian hepatologist’s perspective

Disorders of the Hepatic Veins and Hepatic Sinusoids

Contact Info

Product

Resources

About